GeneDx Holdings Corp Net Income
| WGS Stock | 84.29 0.21 0.25% |
As of the 7th of February, GeneDx Holdings retains the Market Risk Adjusted Performance of (0.40), standard deviation of 3.77, and Risk Adjusted Performance of (0.14). Concerning fundamental indicators, the technical analysis model lets you check existing technical drivers of GeneDx Holdings Corp, as well as the relationship between them. Please check out GeneDx Holdings Corp market risk adjusted performance and treynor ratio to decide if GeneDx Holdings is priced fairly, providing market reflects its last-minute price of 84.29 per share. Given that GeneDx Holdings Corp has information ratio of (0.20), we strongly advise you to confirm GeneDx Holdings Corp's regular market performance to make sure the company can sustain itself at a future point.
GeneDx Holdings Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 5.9507 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -47.1 M | -49.4 M | |
| Net Loss | -494.1 M | -469.4 M | |
| Net Loss | -47.1 M | -49.4 M | |
| Net Loss | (1.75) | (1.84) | |
| Net Income Per E B T | 0.89 | 0.78 |
GeneDx | Net Income | Build AI portfolio with GeneDx Stock |
The evolution of Net Income for GeneDx Holdings Corp provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how GeneDx Holdings compares to historical norms and industry peers.
Latest GeneDx Holdings' Net Income Growth Pattern
Below is the plot of the Net Income of GeneDx Holdings Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in GeneDx Holdings Corp financial statement analysis. It represents the amount of money remaining after all of GeneDx Holdings Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is GeneDx Holdings' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GeneDx Holdings' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (52.29 M) | 10 Years Trend |
|
Net Income |
| Timeline |
GeneDx Net Income Regression Statistics
| Arithmetic Mean | (97,486,510) | |
| Coefficient Of Variation | (141.72) | |
| Mean Deviation | 96,650,701 | |
| Median | (29,704,000) | |
| Standard Deviation | 138,154,277 | |
| Sample Variance | 19086.6T | |
| Range | 519.3M | |
| R-Value | (0.38) | |
| Mean Square Error | 17348.5T | |
| R-Squared | 0.15 | |
| Significance | 0.13 | |
| Slope | (10,520,502) | |
| Total Sum of Squares | 305385.7T |
GeneDx Net Income History
Other Fundumenentals of GeneDx Holdings Corp
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
GeneDx Holdings Net Income component correlations
GeneDx Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for GeneDx Holdings is extremely important. It helps to project a fair market value of GeneDx Stock properly, considering its historical fundamentals such as Net Income. Since GeneDx Holdings' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GeneDx Holdings' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GeneDx Holdings' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Health Care Equipment & Supplies market expansion? Will GeneDx introduce new products? Factors like these will boost the valuation of GeneDx Holdings. Anticipated expansion of GeneDx directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about GeneDx Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.11 | Revenue Per Share | Quarterly Revenue Growth 0.519 | Return On Assets | Return On Equity |
Investors evaluate GeneDx Holdings Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating GeneDx Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause GeneDx Holdings' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between GeneDx Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if GeneDx Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, GeneDx Holdings' market price signifies the transaction level at which participants voluntarily complete trades.
GeneDx Holdings 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to GeneDx Holdings' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of GeneDx Holdings.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in GeneDx Holdings on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding GeneDx Holdings Corp or generate 0.0% return on investment in GeneDx Holdings over 90 days. GeneDx Holdings is related to or competes with Hinge Health, Kymera Therapeutics, TransMedics, Viking Therapeutics, Oscar Health, Immunovant, and Privia Health. GeneDx Holdings is entity of United States More
GeneDx Holdings Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure GeneDx Holdings' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess GeneDx Holdings Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.20) | |||
| Maximum Drawdown | 21.84 | |||
| Value At Risk | (7.88) | |||
| Potential Upside | 4.51 |
GeneDx Holdings Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for GeneDx Holdings' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as GeneDx Holdings' standard deviation. In reality, there are many statistical measures that can use GeneDx Holdings historical prices to predict the future GeneDx Holdings' volatility.| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (0.82) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (0.41) |
GeneDx Holdings February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (0.40) | |||
| Mean Deviation | 2.65 | |||
| Coefficient Of Variation | (557.88) | |||
| Standard Deviation | 3.77 | |||
| Variance | 14.23 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (0.82) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (0.41) | |||
| Maximum Drawdown | 21.84 | |||
| Value At Risk | (7.88) | |||
| Potential Upside | 4.51 | |||
| Skewness | (0.27) | |||
| Kurtosis | 1.99 |
GeneDx Holdings Corp Backtested Returns
GeneDx Holdings Corp holds Efficiency (Sharpe) Ratio of -0.2, which attests that the entity had a -0.2 % return per unit of risk over the last 3 months. GeneDx Holdings Corp exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out GeneDx Holdings' Market Risk Adjusted Performance of (0.40), standard deviation of 3.77, and Risk Adjusted Performance of (0.14) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 1.68, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, GeneDx Holdings will likely underperform. At this point, GeneDx Holdings Corp has a negative expected return of -0.78%. Please make sure to check out GeneDx Holdings' total risk alpha, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if GeneDx Holdings Corp performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.36 |
Poor reverse predictability
GeneDx Holdings Corp has poor reverse predictability. Overlapping area represents the amount of predictability between GeneDx Holdings time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of GeneDx Holdings Corp price movement. The serial correlation of -0.36 indicates that just about 36.0% of current GeneDx Holdings price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.36 | |
| Spearman Rank Test | -0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 315.77 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
GeneDx Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, GeneDx Holdings Corp reported net income of (52.29 Million). This is 115.32% lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 109.16% higher than that of the company.
GeneDx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GeneDx Holdings' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GeneDx Holdings could also be used in its relative valuation, which is a method of valuing GeneDx Holdings by comparing valuation metrics of similar companies.GeneDx Holdings is currently under evaluation in net income category among its peers.
GeneDx Holdings Current Valuation Drivers
We derive many important indicators used in calculating different scores of GeneDx Holdings from analyzing GeneDx Holdings' financial statements. These drivers represent accounts that assess GeneDx Holdings' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of GeneDx Holdings' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 482.0M | 89.2M | 66.9M | 2.1B | 2.4B | 1.2B | |
| Enterprise Value | 114.3M | 28.9M | 86.9M | 2.1B | 1.9B | 2.0B |
GeneDx Holdings ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, GeneDx Holdings' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GeneDx Holdings' managers, analysts, and investors.Environmental | Governance | Social |
GeneDx Fundamentals
| Return On Equity | 0.0084 | ||||
| Return On Asset | 0.0162 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | (0.03) % | ||||
| Current Valuation | 2.39 B | ||||
| Shares Outstanding | 28.9 M | ||||
| Shares Owned By Insiders | 12.32 % | ||||
| Shares Owned By Institutions | 87.68 % | ||||
| Number Of Shares Shorted | 3.62 M | ||||
| Price To Book | 8.33 X | ||||
| Price To Sales | 6.06 X | ||||
| Revenue | 305.45 M | ||||
| Gross Profit | 280.11 M | ||||
| EBITDA | (1.26 M) | ||||
| Net Income | (52.29 M) | ||||
| Total Debt | 116.17 M | ||||
| Book Value Per Share | 10.12 X | ||||
| Cash Flow From Operations | (28.5 M) | ||||
| Short Ratio | 6.68 X | ||||
| Earnings Per Share | 0.11 X | ||||
| Target Price | 170.0 | ||||
| Number Of Employees | 1 K | ||||
| Beta | 2.02 | ||||
| Market Capitalization | 2.44 B | ||||
| Total Asset | 419.38 M | ||||
| Retained Earnings | (1.35 B) | ||||
| Working Capital | 143.15 M | ||||
| Net Asset | 419.38 M |
About GeneDx Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GeneDx Holdings Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneDx Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneDx Holdings Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for GeneDx Stock Analysis
When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.